Skip to main content

Table 2 Most common TRAEsa

From: Osimertinib plus anlotinib for advanced NSCLC with acquired EGFR T790M mutation: results from a multicenter phase II study with ctDNA analysis

AE

Grade 1–2 (%)

Grade 3 (%)

Total patients, no. (%)

Thrombocytopenia

14 (45.2)

1 (3.2)

15 (48.4)

Hypertension

5 (16.1)

9 (29.0)

14 (45.2)

Leucopenia

10 (32.3)

3 (9.7)

13 (41.9)

Neutropenia

10 (32.3)

3 (9.7)

13 (41.9)

Diarrhea

8 (25.8)

1 (3.2)

9 (29.0)

Proteinuria

7 (22.6)

2 (6.5)

9 (29.0)

Serum creatinine increased

8 (25.8)

0 (0)

8 (25.8)

Weight loss

7 (22.6)

1 (3.2)

8 (25.8)

Fatigue

6 (19.4)

1 (3.2)

7 (22.6)

Hypertriglyceridemia

7 (22.6)

0 (0)

7 (22.6)

Hand-foot syndrome

6 (19.4)

0 (0)

6 (19.4)

Oral mucositis

6 (19.4)

0 (0)

6 (19.4)

Hyperuricemia

5 (16.1)

0 (0)

5 (16.1)

Hypothyroidism

5 (16.1)

0 (0)

5 (16.1)

Hypercholesterolemia

4 (12.9)

0 (0)

4 (12.9)

Decreased appetite

4 (12.9)

0 (0)

4 (12.9)

Rash

3 (9.7)

1 (3.2)

4 (12.9)

  1. aMost common TRAEs are those observed in > 10% of patients treated with osimertinib and anlotinib. TRAEs are defined as events that are possibly, probably, or definitely related to osimertinib, anlotinib, or both. AEs, adverse events; TRAEs, treatment-related adverse events